Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 25 Hydroxycholecalciferol
2. 25 Hydroxycholecalciferol Monohydrate
3. 25 Hydroxyvitamin D 3
4. 25 Hydroxyvitamin D3
5. 25-hydroxycholecalciferol
6. 25-hydroxycholecalciferol Monohydrate
7. 25-hydroxyvitamin D 3
8. 25-hydroxyvitamin D3
9. Anhydrous, Calcifediol
10. Calcidiol
11. Calcifediol Anhydrous
12. Calcifediol, (3 Alpha,5z,7e)-isomer
13. Calcifediol, (3 Beta,5e,7e)-isomer
14. Calderol
15. Dedrogyl
16. Hidroferol
17. Monohydrate, 25-hydroxycholecalciferol
1. Calcidiol
2. 25-hydroxyvitamin D3
3. 19356-17-3
4. 25-hydroxycholecalciferol
5. Calcifediol Anhydrous
6. Hidroferol
7. 25-hydroxyvitamin D
8. Calderol
9. Didrogyl
10. Calcifediolum
11. Rayaldee
12. Ro 8-8892
13. 5,6-cis-25-hydroxyvitamin D3
14. Calcifediol [inn]
15. Cholecalciferol, 25-hydroxy-
16. Chebi:17933
17. (3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol
18. T0wxw8f54e
19. 3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol
20. Ncgc00161326-04
21. Calcifidiol
22. Delakmin
23. 25-hydroxy Vitamin D3
24. (3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
25. (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
26. U-32070e
27. U 32070 E
28. 25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / Calcidiol
29. 25-hydroxycholescalciferol
30. Calcifediolum [inn-latin]
31. Rovimix Hy-d
32. (1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
33. (3b,5z,7e)- 9,10-secocholesta-5,7,10(19)-triene-3,25-diol
34. Vitamin D, 25-hydroxy-
35. Hy-d
36. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
37. 36149-00-5
38. 25-(oh)vitamin D3
39. 5,6-trans-25-hydroxycholescalciferol
40. Unii-t0wxw8f54e
41. Ryaldee
42. Bml2-e02
43. (5z,7e)-(3s)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
44. 25(oh)d3
45. Einecs 242-990-9
46. Mfcd00867077
47. U 32070e
48. Calcifediol [mi]
49. (5z,7e)-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
50. 5,6-trans-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
51. Spectrum5_001931
52. Dsstox_cid_2721
53. 25-hydroxy-cholecalciferol
54. Calcifediol,anhydrous
55. Schembl3296
56. Chembl1040
57. Dsstox_rid_76699
58. Dsstox_gsid_22721
59. Bspbio_001411
60. Calcifediol, Anhydrous
61. (3s,5z,7e)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
62. Gtpl6921
63. Dtxsid0022721
64. Chebi:94743
65. Amy2863
66. Bcpp000306
67. Dm100
68. Hms1361g13
69. Hms1791g13
70. Hms1989g13
71. Hms2089l21
72. Hms3402g13
73. 64719-49-9
74. Act06833
75. Zinc4474414
76. Tox21_111987
77. (3s,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
78. 9,10-secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5z,7e)-
79. Bdbm50521013
80. Calcifediol,anhydrous [vandf]
81. Lmst03020246
82. S1469
83. Akos015965097
84. Bcp9000472
85. Ccg-268657
86. Cs-0800
87. Db00146
88. Idi1_033881
89. Ncgc00161326-01
90. Ac-31367
91. Hy-32351
92. Cas-19356-17-3
93. 25-hydroxycholecalciferol, >=98% (hplc)
94. C01561
95. Ab01275461-01
96. Ab01275461_02
97. 356c173
98. A923587
99. Q139307
100. Sr-05000001468
101. Sr-05000001468-1
102. W-201718
103. 25-hydroxyvitamin D3 Monohydrate, >=99.0% (hplc)
104. 9,10-secocholesta-5,7,10(19)-triene-3b,25-diol
105. Brd-k77175907-001-01-5
106. B91135ec-8937-4d8b-a533-ccd82f33c1b0
107. Calcifediol, European Pharmacopoeia (ep) Reference Standard
108. (5e,7e)-9,10-secocholesta-5,7,10(19)-triene-3beta,25-diol
109. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, 98% (cp)
110. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, 98% (cp)
111. 25-hydroxyvitamin D3 Solution, 50 Mug/ml In Ethanol, 98% (cp)
112. Calcifediol, United States Pharmacopeia (usp) Reference Standard
113. (3s,5z,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-3,25-diol
114. (5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3b,25-diol Monohydrate
115. 9,10-secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5z,7e)-
116. (?r,1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1h-indene-1-pentanol
117. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol
118. (s,z)-3-((e)-2-((1r,3as,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol
119. 1h-indene-1-pentanol, Octahydro-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.r,1r,3as,4e,7ar)-
120. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material
121. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 400.6 g/mol |
---|---|
Molecular Formula | C27H44O2 |
XLogP3 | 6.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 6 |
Exact Mass | 400.334130642 g/mol |
Monoisotopic Mass | 400.334130642 g/mol |
Topological Polar Surface Area | 40.5 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 655 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
Treatment of secondary hyperparathyroidism (SHPT)
Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)
A - Alimentary tract and metabolism
A11 - Vitamins
A11C - Vitamin a and d, incl. combinations of the two
A11CC - Vitamin d and analogues
A11CC06 - Calcifediol
H - Systemic hormonal preparations, excl. sex hormones and insulins
H05 - Calcium homeostasis
H05B - Anti-parathyroid agents
H05BX - Other anti-parathyroid agents
H05BX05 - Calcifediol
Absorption
Readily absorbed.
Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.
288 hours
Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15564
Submission : 2001-08-02
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-07-28
Pay. Date : 2016-07-08
DMF Number : 21963
Submission : 2008-09-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33640
Submission : 2019-05-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12386
Submission : 1997-02-27
Status : Inactive
Type : II
Certificate Number : CEP 1998-059 - Rev 09
Status : Valid
Issue Date : 2024-12-02
Type : Chemical and TSE
Substance Number : 1295
Certificate Number : CEP 2019-163 - Rev 02
Status : Valid
Issue Date : 2024-08-27
Type : Chemical
Substance Number : 1295
Certificate Number : R0-CEP 2022-335 - Rev 00
Status : Valid
Issue Date : 2022-11-29
Type : Chemical
Substance Number : 1295
Certificate Number : R0-CEP 2015-359 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2022-08-09
Type : Chemical
Substance Number : 1295
Certificate Number : R1-CEP 1999-101 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2012-06-07
Type : Chemical
Substance Number : 1295
NDC Package Code : 45408-002
Start Marketing Date : 2012-08-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66499-0065
Start Marketing Date : 2019-09-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...
About the Company : DISHMAN Netherlands is located in Veenendaal in the middle of the Netherlands. We are active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol a...
About the Company : DongWha is the company that "serves customers by making good medicines and is managed with the rewards generated by benefits of good medicines." Under its corporate philosophy that...
About the Company : Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspecti...
About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...
About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...
About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...
Details:
RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Lead Product(s): Calcifediol
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Vifor Fresenius Medical Care Renal Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Lead Product(s) : Calcifediol
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Vifor Fresenius Medical Care Renal Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Brand Name : Rayaldee
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 03, 2022
Details:
RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a 2-week follow-up.
Lead Product(s): Calcifediol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2021
Lead Product(s) : Calcifediol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a...
Brand Name : Rayaldee
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2021
Details:
Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact iPTH.
Lead Product(s): Calcifediol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2021
Lead Product(s) : Calcifediol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact ...
Brand Name : Rayaldee
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2021
Details:
OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.
Lead Product(s): Calcifediol
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CSL Vifor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 24, 2021
Lead Product(s) : Calcifediol
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL Vifor
Deal Size : Undisclosed
Deal Type : Termination
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
Details : OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.
Brand Name : Rayaldee
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 24, 2021
Details:
The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).
Lead Product(s): Calcifediol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Lead Product(s) : Calcifediol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients
Details : The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).
Brand Name : Rayaldee
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2020
Details:
The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.
Lead Product(s): Calcifediol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Lead Product(s) : Calcifediol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients
Details : The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2020
Regulatory Info :
Registration Country : Italy
Brand Name : DIDROGYL
Dosage Form : Oral Drops Solution
Dosage Strength : 1.5 mg/10 ml
Packaging : 10 ML 0.15 MG/ML - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Rayaldee
Dosage Form : Caps
Dosage Strength : 30mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : VIDENKA
Dosage Form : Oral Drops Solution
Dosage Strength : 0.15 mg/ml
Packaging : 10 ML 0.15 MG/ML - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Didrogyl
Dosage Form : Calcifediolo 1,5Mg/10Ml Oral Use
Dosage Strength : os gtt soluz 1.5 mg 10 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company :
Calcifediol
Drug Cost (USD) : 36,135,698
Year : 2022
Prescribers : 4175
Prescriptions : 26091
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 39,639,508
Year : 2021
Prescribers : 4919
Prescriptions : 28393
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 61,315,676
Year : 2020
Prescribers : 6792
Prescriptions : 44119
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 45,863,706
Year : 2019
Prescribers : 6659
Prescriptions : 34106
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 20,943,011
Year : 2018
Prescribers : 3736
Prescriptions : 17194
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 5,122,073
Year : 2017
Prescribers : 1333
Prescriptions : 4255
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 19,456
Year : 2016
Prescribers : 16
Prescriptions : 16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Calcifediol
Drug Cost (USD) : 0
Year : 2015
Prescribers :
Prescriptions : 0
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
03 Feb 2021
Patents & EXCLUSIVITIES
Patent Expiration Date : 2028-08-27
US Patent Number : 8426391
Drug Substance Claim :
Drug Product Claim :
Application Number : 208010
Patent Use Code : U-1872
Delist Requested :
Patent Use Description : USE OF SUSTAINED RELEA...
Patent Expiration Date : 2028-08-27
Patent Expiration Date : 2028-04-25
US Patent Number : 8778373
Drug Substance Claim :
Drug Product Claim :
Application Number : 208010
Patent Use Code : U-1873
Delist Requested :
Patent Use Description : ADMINISTRATION OF 25-H...
Patent Expiration Date : 2028-04-25
REF. STANDARDS & IMPURITIES
Calcifediol - reference spectrum
Calcifediol - reference spectrum
CAS Number : n/a
Quantity Per Vial : n/a
Sale Unit : 1
Order Code : C0166001
Batch No : 1
Price (€) : 79
Storage :
Calcifediol
CAS Number : 63283-36-3
Quantity Per Vial : 5 mg
Sale Unit : 1
Order Code : C0166000
Batch No : 6
Price (€) : 150
Storage : -20°C ± 5°C
ABOUT THIS PAGE
A Calcifediol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcifediol, including repackagers and relabelers. The FDA regulates Calcifediol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcifediol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Calcifediol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Calcifediol supplier is an individual or a company that provides Calcifediol active pharmaceutical ingredient (API) or Calcifediol finished formulations upon request. The Calcifediol suppliers may include Calcifediol API manufacturers, exporters, distributors and traders.
click here to find a list of Calcifediol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Calcifediol DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcifediol active pharmaceutical ingredient (API) in detail. Different forms of Calcifediol DMFs exist exist since differing nations have different regulations, such as Calcifediol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Calcifediol DMF submitted to regulatory agencies in the US is known as a USDMF. Calcifediol USDMF includes data on Calcifediol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcifediol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Calcifediol suppliers with USDMF on PharmaCompass.
A Calcifediol CEP of the European Pharmacopoeia monograph is often referred to as a Calcifediol Certificate of Suitability (COS). The purpose of a Calcifediol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcifediol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcifediol to their clients by showing that a Calcifediol CEP has been issued for it. The manufacturer submits a Calcifediol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcifediol CEP holder for the record. Additionally, the data presented in the Calcifediol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcifediol DMF.
A Calcifediol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcifediol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Calcifediol suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calcifediol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Calcifediol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Calcifediol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Calcifediol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calcifediol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Calcifediol suppliers with NDC on PharmaCompass.
Calcifediol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Calcifediol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcifediol GMP manufacturer or Calcifediol GMP API supplier for your needs.
A Calcifediol CoA (Certificate of Analysis) is a formal document that attests to Calcifediol's compliance with Calcifediol specifications and serves as a tool for batch-level quality control.
Calcifediol CoA mostly includes findings from lab analyses of a specific batch. For each Calcifediol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Calcifediol may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcifediol EP), Calcifediol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcifediol USP).
LOOKING FOR A SUPPLIER?